BTI-Biotechnology Institute, Vitoria, Spain; University Institute for Regenerative Medicine & Oral Implantology, UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain.
BTI-Biotechnology Institute, Vitoria, Spain; University Institute for Regenerative Medicine & Oral Implantology, UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain.
J Tissue Viability. 2021 May;30(2):183-189. doi: 10.1016/j.jtv.2021.02.011. Epub 2021 Mar 4.
Cutaneous autoimmune and inflammatory diseases are a major burden of global disease and many lack effective treatments that can derive in different dermatoses like atopic dermatitis. Despite the increase prevalence and the high health-care costs worldwide, the heterogeniety and multifactoriality of these diseases mean that effective treatment options are scarce. Plasma rich in growth factors (PRGF) technology could be an alternative approach that may help in the management of this cutaneous condition. The aim of this study was to assess the effect of two different PRGF formulations (just activated and autologous topical serum (ATS)) for the management of skin inflammation. Additionally, ATS was assessed over two patients suffering from radiotherapy induced dermatitis. Human organotypic skin explant cultures (hOSECs) were used as human skin models. To induce atopic dermatitis-like conditions, skin explants were treated with both interleukin-4 (IL-4) and interleukin-13 (IL-13). PRGF and ATS were intradermally and topically applied, respectively. Metabolic activity, reactive oxigen species (ROS), necrosis and inflammatory cytokine production were determined. Both PRGF formulations increased tissue viability and significantly reduced the excessive free radical accumulation and the cutaneous cytokine production such as TNF-α and IL-1β. Case reports showed a positive response after ATS treatment in terms of skin quality improvement, local erythema decrease and burning and itching amelioration. The oedema, swelling and desquamation caused by radiation induced dermatitis was also reduced and the patients referred ceased pruritus and pain. This preliminary study suggests that PRGF might aid in the management of inflammatory skin conditions.
皮肤自身免疫和炎症性疾病是全球疾病的主要负担，许多疾病缺乏有效的治疗方法，这可能导致不同的皮肤病，如特应性皮炎。尽管这些疾病在全球的患病率不断上升，且医疗保健费用高昂，但它们的异质性和多因素性意味着有效的治疗选择仍然有限。富含生长因子的血浆（PRGF）技术可能是一种替代方法，可以帮助治疗这种皮肤状况。本研究旨在评估两种不同 PRGF 制剂（即激活和自体局部血清（ATS））在皮肤炎症管理中的作用。此外，还评估了 ATS 在两名放射性皮炎患者中的应用。人器官型皮肤外植体培养物（hOSECs）被用作人类皮肤模型。为了诱导特应性皮炎样条件，皮肤外植体用白细胞介素-4（IL-4）和白细胞介素-13（IL-13）处理。PRGF 和 ATS 分别通过皮内和局部应用。测定代谢活性、活性氧（ROS）、坏死和炎症细胞因子的产生。两种 PRGF 制剂均增加了组织活力，并显著减少了过多的自由基积累和 TNF-α和 IL-1β等皮肤细胞因子的产生。病例报告显示，ATS 治疗后，皮肤质量改善、局部红斑减少、烧灼感和瘙痒减轻。放射诱导性皮炎引起的水肿、肿胀和脱屑也减少，患者瘙痒和疼痛减轻。这项初步研究表明，PRGF 可能有助于管理炎症性皮肤疾病。
